Active ingredients: antithymocyte immunoglobulin equine
What it is used for
INDICATIONS AS AT 11 APRIL 2002 : ATGAM is indicated for renal transplant patients in whom reduction of peripheral T-lympocyte function as measured by rosette-forming cell assay could be desirable. During controlled clinical trials, this immunosuppression has been demonstrated in renal allograft recipients treated with ATGAM. When it was administered prophylactically with conventional immunosuppressive therapy, ATGAM delayed the onset of the first rejection episode, and when it was administered at the time of the first rejection, ATGAM resolved the acute rejection episode more frequently than did conventional therapy alone.
How to take it
The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear to straw coloured solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient antithymocyte immunoglobulin equine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems